Fate reports initial Phase I data for Fate-NK100 in AML

Fate Therapeutics Inc. (NASDAQ:FATE) reported preliminary data from 2 patients with relapsed or refractory acute myelogenous leukemia (AML) in the Phase I VOYAGE trial evaluating single doses of IV Fate-NK100. At day 14, a patient receiving 2x10⁷ cells/kg Fate-NK100 achieved a morphologic leukemia-free state, and a patient receiving 1x10⁷ cells/kg Fate-NK100 had a reduction of leukemic blasts of "nearly" 50%. No dose-limiting toxicities (DLTs) were reported. Data were presented at the Society for Immunotherapy of Cancer meeting in National Harbor, Md.

The trial is evaluating 3 dose cohorts of 1x10⁷, 2x10⁷ and up to 1x10⁸ cells/kg Fate-NK100 as monotherapy after lymphodepleting chemotherapy followed by subcutaneous IL-2, with each cohort enrolling 1 patient. The open-label, U.S. trial includes a 10-patient expansion cohort at the maximum dose level...